G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for High-risk MDS Undergoing Allo-HSCT

• Status: Recruiting
• Trial end date: 2024-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Allo-HSCT is the most effective way to cure high-risk MDS patients. At present, the best conditioning regimen for high-risk MDS patients undergoing allo-HSCT remains in discussion. In this prospective study, the safety and efficacy of G-CSF+DAC+BUCY and G-CSF+DAC+BF conditioning regimens in high-risk MDS patients undergoing allo-HSCT are evaluated.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Nanfang Hospital of Southern Medical University
• Collaborators: First People's Hospital of Chenzhou; Guangzhou First People's Hospital; Institute of Hematology and Blood Diseases Hospital; Peking University People's Hospital; Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; The Seventh Affiliated Hospital of Sun Yat-sen University
• Treatments: Busulfan; Cyclophosphamide; Decitabine; Fludarabine; Lenograstim

Criteria

Inclusion Criteria:

• Had a diagnosis of RAEB-1 or RAEB-2 with IPSS-R >3

• Age 18 to 65 years old

• ECOG performance status of 0-2

• HCT-CI of 0-2

• Were willing to undergo allo-HSCT

Exclusion Criteria:

• Therapy-related MDS

• Previous allo-HSCT

• Uncontrolled infections

• Liver or renal dysfunction

• Severe concomitant conditions not suitable for the trial